| domain | finding | evidence type/strength | key source/date |
|---|---|---|---|
| identity/identifier | Dilated cardiomyopathy 1JJ is represented in Open Targets as MONDO_0014095 and is linked there to **LAMA4**; this is an aggregated disease-resource assertion rather than a patient-level record. | Aggregated database evidence; moderate for identifier mapping, limited for full clinical characterization | Open Targets disease-target association (MONDO_0014095 ↔ LAMA4), accessed via context (pqac-00000000) |
| causal gene | **LAMA4** (laminin subunit alpha 4; MIM 600133) is the asserted causal gene for DCM1JJ in disease-gene resources and is discussed in recent cardiomyopathy “minor gene” literature. | Disease-gene association supported by historical reports and review synthesis; currently limited/secondary evidence | Micolonghi et al., *Int J Mol Sci* 2024 (pqac-00000007) |
| reported variants | Reported disease-associated variants include **p.(Pro943Leu)** and **p.(Arg1073\*)**, described as lying in an **integrin-interacting domain** of LAMA4. | Historical human variant reports summarized in review; direct primary-case details not available in retrieved text | Micolonghi et al., 2024 (pqac-00000007) |
| human evidence | Human evidence consists of reported DCM patients carrying the above LAMA4 variants; the retrieved evidence supports existence of such reports but does **not** provide enough detail here on case count, segregation, penetrance, or full phenotype spectrum. | Human genetic evidence present but sparse in available context; strength limited | Open Targets cites PMID 17646580; review summary in Micolonghi et al., 2024 (pqac-00000000, pqac-00000007) |
| mechanism | Proposed mechanism: LAMA4 variants disrupt **laminin–integrin interactions**, impairing cellular adhesion and signal transduction pathways important for cardiac structural integrity and stress responses. | Mechanistic inference from variant location plus model data; plausible but not fully resolved in humans | Micolonghi et al., 2024 (pqac-00000007) |
| animal models | **Lama4-deficient mice** show cardiovascular defects including endothelial disruption/hemorrhage and later cardiac hypertrophy/heart failure; **zebrafish LAMA4 knockdown** causes severe cardiac dysfunction and hemorrhages. | In vivo model evidence; moderate for biological plausibility, indirect for human disease causality | Micolonghi et al., 2024 (pqac-00000007); supporting mouse background noted in Lama4-null literature snippet (pqac-00000000) |
| current gene-validity caveat | Contemporary literature frames LAMA4 as a **minor cardiomyopathy gene**; available retrieved evidence does not establish it here as a universally accepted, definitively validated high-evidence DCM gene. | Important caveat; evidence strength limited/uncertain | Micolonghi et al., 2024 narrative review of minor genes (pqac-00000007) |
| diagnosis | No DCM1JJ-specific diagnostic criteria were found. For DCM generally, diagnosis relies on imaging-confirmed LV dilatation and systolic dysfunction unexplained by loading conditions/CAD; echocardiography is first-line and CMR is important for phenotyping and fibrosis detection. | Strong for general DCM practice; indirect for DCM1JJ | Arnautu et al., 2024 (pqac-00000004); Gasior, 2024 (pqac-00000005, pqac-00000006) |
| treatment | No genotype-specific therapy for DCM1JJ was found. Management should follow standard **HFrEF/DCM guideline-directed therapy** when systolic dysfunction is present; evidence in the retrieved set emphasizes modern multidrug therapy frameworks rather than LAMA4-specific interventions. | Strong for general HFrEF/DCM care; absent for DCM1JJ-specific treatment | MacDonald et al., 2023 guideline comparison (context summarized in search results); general cardiomyopathy management framing in 2024 reviews (pqac-00000005, pqac-00000006) |
| prognosis | No DCM1JJ-specific natural history was found. In nonischemic DCM broadly, **LGE presence/extent** on CMR is strongly associated with mortality, arrhythmic events, and HF events; pediatric DCM remains severe, with review-level estimates noting nearly **40%** transplant or death within 2 years. | Strong for general DCM prognostic markers; absent for DCM1JJ-specific outcomes | Eichhorn et al., *JAMA* 2024 (pqac-00000001, pqac-00000002); Malinow et al., 2024 (pqac-00000003) |
| evidence gaps | Major gaps: no retrieved disease-specific prevalence/incidence, no robust cohort statistics, no detailed segregation/penetrance data in available context, no validated modifier/protective factors, no DCM1JJ-specific biomarkers, no targeted therapies, and no direct quality-of-life or prevention studies. | High-confidence statement of missing evidence | Synthesis of available contexts (pqac-00000000, pqac-00000007, pqac-00000004, pqac-00000005, pqac-00000006, pqac-00000001, pqac-00000003) |


*Table: This table condenses the currently retrievable evidence for Dilated Cardiomyopathy 1JJ, separating disease-specific findings from broader dilated cardiomyopathy guidance. It is useful for knowledge-base curation because it highlights both what is supported and what remains uncertain.*